{
    "title": "Roche believes cancer drug setback not a fatal blow to growth prospects",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10810057/Roche-says-cancer-setback-cushioned-drug-development.html",
    "date": "2022-05-12",
    "keywords": [
        "drug",
        "franz",
        "cancer",
        "growth",
        "trial",
        "disease",
        "company",
        "roche",
        "research",
        "burger",
        "tiragolumab",
        "form",
        "gantenerumab",
        "treatment",
        "reporting",
        "paul",
        "arnold",
        "zurich",
        "ag",
        "development",
        "pipeline",
        "setback",
        "chairman",
        "christoph",
        "thursday",
        "stock",
        "day",
        "march",
        "analysis",
        "progression",
        "lung",
        "course",
        "companys",
        "board",
        "advantage",
        "size",
        "latestage",
        "reward",
        "prospect",
        "arsenal",
        "year",
        "field",
        "memoryrobbing",
        "profile",
        "adoption",
        "biogen",
        "inc",
        "health",
        "regulator",
        "evidence",
        "benefit",
        "part",
        "lack",
        "mindwasting",
        "everyone",
        "type",
        "blood",
        "glofitamab",
        "demand",
        "focus",
        "maker",
        "use",
        "mass",
        "spectrometry",
        "healthcare",
        "method",
        "investment",
        "downturn",
        "biotech",
        "sector",
        "reach",
        "note",
        "month",
        "market",
        "room",
        "viability",
        "interest",
        "grover",
        "editing",
        "shumaker",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}